Why Heron Therapeutics, Inc.’s (HRTX) Stock Is Down 5.69%
As of Wednesday, August 26, Heron Therapeutics, Inc.’s HRTX share price has dipped by 5.69%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Commentary & Analysis
Why Heron Therapeutics, Inc.’s (HRTX) Stock Is Down 5.16%
As of Tuesday, August 18, Heron Therapeutics, Inc.’s HRTX share price has dipped by 5.16%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Heron Therapeutics, Inc.’s (HRTX) Stock Is Up 9.14%
As of Wednesday, August 12, Heron Therapeutics, Inc.’s HRTX share price has surged by 9.14%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Heron Therapeutics, Inc.’s (HRTX) Stock Is Down 8.09%
As of Tuesday, August 11, Heron Therapeutics, Inc.’s HRTX share price has dipped by 8.09%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Heron Therapeutics, Inc.’s (HRTX) Stock Is Down 27.16%
As of Monday, August 10, Heron Therapeutics, Inc.’s HRTX share price has dipped by 27.16%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | HRTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $59.8 | $282.5 | 17% |
|
| Shares Out (Mil) | 190.3 | 54.1 | 75% |
|
| Institutional Ownership | 98.0% | 92.9% | 77% |
|
| Float (Mil) | 146.5 | 41.5 | 69% |
|
| Beta | 1.66 | 0.94 | 86% |
|
| Avg Daily Volume (000s) | 2,245 | 469 | 85% |
|
| Price Change (52-week) |
(76.7%) | 59.1% | 7% |
|
| Growth | HRTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.8% | 14.1% | 64% |
|
| Net Income (5yr) | 38.4% | (10.1%) | 90% |
|
| EPS (5yr) | 45.4% | 15.9% | 91 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (44.2%) | (15.6%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.025) | ($0.130) | ($0.110) | |
| Month Ago EPS | ($0.020) | ($0.090) | $0.000 | |
| # Rev Up | 0 | 0 | 2 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.020) | ($0.090) | $0.000 | |
| Year/Year Chg | (16.7%) | 7.4% | (54.5%) | |
| Financials | HRTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $151 | $37 | 29% |
|
| Net Income (TTM) (Mil) | ($34) | ($43) | 19% |
|
| EPS (TTM) | ($0.184) | ($1.500) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $2 | 51% |
|
| Long-Term Debt (Q1) (Mil) | $148 | $4 | 47% |
|
| Enterprise Value (Q1) (Mil) | $168 | $195 | 25% |
|
| Valuation | HRTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.50 | 2.78 | 91% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | HRTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.9% | 66.9% | 74% |
|
| Net Margin | (22.5%) | (74.2%) | 16% |
|
| ROA | (14.1%) | (47.6%) | 23% |
|
| ROE | 318.2% | (55.0%) | 99% |
|
| Liabilities to Assets | 97.3% | 29.6% | 93% |
|
| F-Score | 2 | 3 | na |
|
Heron Therapeutics, Inc. did not pass any screens on 9/1/2026.
